Muhammad_Usman_Complete_mRNA_LNP_Research_Paper.pdf

Messenger RNA (mRNA) vaccines represent a revolutionary advancement in immunization technology, offering rapid development, modular antigen design, and scalable manufacturing. However, their effectiveness relies heavily on the delivery system employed to protect and shuttle mRNA into host cells. Lipid nanoparticles (LNPs) are the most widely used vectors for mRNA delivery, as demonstrated by the success of COVID-19 vaccines. Despite this, traditional LNPs face limitations such as low stability, moderate immunogenicity, and unfavorable biodistribution. This study investigates and compares five LNP systems—Conventional, Crosslinked, PEG-Free, Zn-Coordinated, and Dendrimer based—based on encapsulation efficiency, stability, immunogenic response, and organ specific biodistribution. Results show that Crosslinked LNPs offer the highest encapsulation efficiency (92%) and CD8+ T-cell activation (5.8-fold), while PEG-Free and Dendrimer based LNPs show enhanced targeting to spleen and lymph nodes, vital for immune modulation. Our findings highlight design opportunities for optimizing mRNA vaccine delivery, which is critical to advancing global immunization efforts and meeting U.S. national interest goals in biotechnology.